NDAINTRAVENOUSEMULSION
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
CINVANTI (aprepitant) by Heron Therapeutics is neurokinin 1 antagonists [moa]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINVANTI is an intravenous emulsion formulation of aprepitant, a neurokinin-1 (NK-1) receptor antagonist approved in 2017 for chemotherapy-induced nausea and vomiting (CINV) prevention. It works by blocking substance P signaling in the brain's chemoreceptor trigger zone, complementing 5-HT3 antagonists and corticosteroids in CINV management. The IV formulation offers rapid onset and improved convenience compared to oral alternatives.
$0.142MPart D
Peak9.0 years to LOEProduct is at peak lifecycle with modest Medicare utilization (201 Part D claims in 2023), suggesting a stable but niche market requiring focused medical and sales strategies.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Aprepitant to Improve Same Day Discharge for TKA
Started Jul 2026
350 enrolled
PONV
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Started Feb 2024
518 enrolled
Postoperative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Started Jul 2020
27 enrolled
COVID-19
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Worked on CINVANTI at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.